Switch theme
Sign up to access all valuation multiples
HLB Life Science Co Ltd and its subsidiaries are engaged in the medicare business, bio development business, medical device business, and drug distribution business. The company is a medical device for in vitro diagnostics.The main business is the Medicare business, which includes foot and manufacturing, quasi-drug component development, and finished product consignment production.
1998
n/a
Last FY Revenue $74.9M
Last FY EBITDA $19.0M
$476M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, HLB Life Science achieved revenue of $74.9M and an EBITDA of $19.0M.
HLB Life Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HLB Life Science valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $74.9M | XXX | XXX | XXX |
| Gross Profit | XXX | -$1.6M | XXX | XXX | XXX |
| Gross Margin | XXX | -2% | XXX | XXX | XXX |
| EBITDA | XXX | $19.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 25% | XXX | XXX | XXX |
| EBIT | XXX | -$15.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | -21% | XXX | XXX | XXX |
| Net Profit | XXX | $4.5M | XXX | XXX | XXX |
| Net Margin | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | $51.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 11, 2025, HLB Life Science's stock price is KRW 4660 (or $3).
HLB Life Science has current market cap of KRW 568B (or $416M), and EV of KRW 649B (or $476M).
See HLB Life Science trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $476M | $416M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 11, 2025, HLB Life Science has market cap of $416M and EV of $476M.
HLB Life Science's trades at 6.3x EV/Revenue multiple, and 25.1x EV/EBITDA.
Equity research analysts estimate HLB Life Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HLB Life Science's P/E ratio is not available.
See valuation multiples for HLB Life Science and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $416M | XXX | $416M | XXX | XXX | XXX |
| EV (current) | $476M | XXX | $476M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 25.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -30.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 92.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHLB Life Science's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
HLB Life Science's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HLB Life Science's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for HLB Life Science and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| ADNOC Drilling Company | XXX | XXX | XXX | XXX | XXX | XXX |
| ADNOC Gas | XXX | XXX | XXX | XXX | XXX | XXX |
| Dana Gas | XXX | XXX | XXX | XXX | XXX | XXX |
| TAQA | XXX | XXX | XXX | XXX | XXX | XXX |
| AGL Energy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HLB Life Science acquired XXX companies to date.
Last acquisition by HLB Life Science was XXXXXXXX, XXXXX XXXXX XXXXXX . HLB Life Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was HLB Life Science founded? | HLB Life Science was founded in 1998. |
| Where is HLB Life Science headquartered? | HLB Life Science is headquartered in South Korea. |
| Who is the CEO of HLB Life Science? | HLB Life Science's CEO is Mr. Sang-woo Nam. |
| Is HLB Life Science publicy listed? | Yes, HLB Life Science is a public company listed on KRX. |
| What is the stock symbol of HLB Life Science? | HLB Life Science trades under 067630 ticker. |
| When did HLB Life Science go public? | HLB Life Science went public in 2008. |
| Who are competitors of HLB Life Science? | Similar companies to HLB Life Science include e.g. ADNOC Drilling Company, ADNOC Gas, Dana Gas, TAQA. |
| What is the current market cap of HLB Life Science? | HLB Life Science's current market cap is $416M |
| Is HLB Life Science profitable? | Yes, HLB Life Science is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
